— Know what they know.
Not Investment Advice

AVRO NASDAQ

AVROBIO, Inc.
1W: -4.8% 1M: +1.4% 3M: +12.0% 1Y: +41.4% 3Y: -85.0% 5Y: -90.4%
$1.40
Last traded 2024-06-21 — delisted
NASDAQ · Healthcare · Biotechnology · $5.2M mcap · 3M float · 0.749% daily turnover

Cash Flow Trends

Operating Cash Flow
-$60M -1.7% ▼
Capital Expenditures
$208K -33.3% ▼
5Y CAGR: -29.3%
Free Cash Flow
-$60M -1.8% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$113M +0.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$119M-$106M$12M-$58M-$74M
Depreciation & Amort.$1M$1M$617K$2M$1M
Stock-Based Comp.$19M$12M$7M$3M$10M
Change in Working Capital$1M-$7M-$4M$0$0
Other Non-Cash Items-$174K$3M-$79M-$6M$2M
Operating Cash Flow-$98M-$97M-$63M-$59M-$60M
— Investing Activities —
Capital Expenditures-$2M-$267K-$8K-$156K-$208K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$0$0
Other Investing$0$0$84M$0$70K
Investing Cash Flow-$2M-$267K$85M-$156K-$138K
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased-$205K$0$86K$0$0
Dividends Paid$0$0$0$0$0
Other Financing$30M$262K-$16M$172M$173M
Financing Cash Flow$30M$262K-$16M$172M$173M
Net Change in Cash-$70M-$97M$6M$112M$113M
Cash End of Period$190M$93M$99M$142M$255M
Free Cash Flow-$100M-$97M-$63M-$59M-$60M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms